Derek Murphy

Derek Murphy

Auto-generated profile, based on publicly available information

Derek Murphy

Center for Human Proteomics, Royal College of Surgeons in Ireland, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2002 in Analytical Biochemistry
Verified
Journal Article
Closed access
PAPhilipp Angenendt
Philipp Angenendt
JGJörn Glökler
Jörn Glökler
DMDerek Murphy
Derek Murphy
HLHans Lehrach
Hans Lehrach
DCDolores J Cahill
Dolores J Cahill

1 August 2009 in Journal of Proteomics
Verified
Journal Article
Closed access
GKGregor Kijanka
Gregor Kijanka
DMDerek Murphy
Derek Murphy

17 January 2006 in Proteomics
Verified
Journal Article
Closed access
PDF file
SHSabine Horn
Sabine Horn
ALAngelika Lueking
Angelika Lueking
DMDerek Murphy
Derek Murphy
ASAlexander Staudt
Alexander Staudt
CGClaudia Gutjahr
Claudia Gutjahr
DCDolores J. Cahill
Dolores J. Cahill

1 June 1994 in Genomics
Verified
Journal Article
Closed access
DMDerek B. Murphy
Derek B. Murphy
SWStefan Wiese
Stefan Wiese
PBPeter Burfeind
Peter Burfeind
DSDaphne Schmundt
Daphne Schmundt
MMMarie- Genevieve Mattei
Marie- Genevieve Mattei
UTUlrike Thies
Ulrike Thies

13 October 2009 in Gut
Verified
Journal Article
Closed access
PDF file
GKG Kijanka
G Kijanka
SHS Hector
S Hector
EKE W Kay
E W Kay
FMF Murray
F Murray
RCR Cummins
R Cummins
DKD Kenny
D Kenny
Objective: Patients with cancer have antibodies against tumour antigens. Characterising the antibody repertoire may provide insights into aberrant cellular mechanisms in cancer development, ultimately leading to novel diagnostic or therapeutic targets. The aim of this study was to characterise the antibody profiles in patients whose symptoms warranted colonoscopy, to see if there was a difference in patients with and without colorectal cancer. Methods: Patients were recruited from a colonoscopy clinic. Individual serum samples from 43 patients with colorectal cancer and 40 patients with no cancer on colonoscopy were profiled on a 37 830 clone recombinant human protein array. Antigen expression was evaluated by quantitative reverse transcription-PCR and by immunohistochemistry on tissue microarrays. Results: Using a sex- and age-matched training set, 18 antigens associated with cancer and 4 associated with the absence of cancer (p<0.05) were identified and confirmed. To investigate the mechanisms triggering antibody responses to these antigens, antigen expression was examined in normal colorectal mucosa and colorectal carcinoma of the same patients. The identified antigens showed cellular accumulation (p53), aberrant cellular expression (high mobility group B1 (HMGB1)) and overexpression (tripartite motif-containing 28 (TRIM28), p53, HMGB1, transcription factor 3 (TCF3), longevity assurance gene homologue 5 (LASS5) and zinc finger protein 346 (ZNF346)) in colorectal cancer tissue compared with normal colorectal mucosa. Conclusions: It is demonstrated for the first time that screening high-density protein arrays identifies unique antibody profiles that discriminate between symptomatic patients with and without colorectal cancer. The differential expression of identified antigens suggests their involvement in aberrant cellular mechanisms in cancer.

1 June 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
DLDeirdre Larkin
Deirdre Larkin
DMDerek Murphy
Derek Murphy
DRDermot F. Reilly
Dermot F. Reilly
MCMartha Cahill
Martha Cahill
ESEllen Sattler
Ellen Sattler
NMNiamh Moran
Niamh Moran
A critical role for the conserved α-integrin cytoplasmic motif, KVGFFKR, is recognized in the regulation of activation of the platelet integrin αIIbβ3. To understand the molecular mechanisms of this regulation, we sought to determine the nature of the protein interactions with this cytoplasmic motif. We used a tagged synthetic peptide, biotin-KVGFFKR, to probe a high density protein expression array (37,200 recombinant human proteins) for high affinity interactions. A number of potential integrin-binding proteins were identified. One such protein, a chloride channel regulatory protein, ICln, was characterized further because its affinity for the integrin peptide was highest as was its expression in platelets. We verified the presence of ICln in human platelets by PCR, Western blots, immunohistochemistry, and its co-association with αIIbβ3 by surface plasmon resonance. The affinity of this interaction was 82.2 ± 24.4 nm in a cell free assay. ICln co-immunoprecipitates with αIIbβ3 in platelet lysates demonstrating that this interaction is physiologically relevant. Furthermore, immobilized KVGFFKR peptides, but not control KAAAAAR peptides, specifically extract ICln from platelet lysates. Acyclovir (100 μm to 5 mm), a pharmacological inhibitor of the ICln chloride channel, specifically inhibits integrin activation (PAC-1 expression) and platelet aggregation without affecting CD62 P expression confirming a specific role for ICln in integrin activation. In parallel, a cell-permeable peptide corresponding to the potential integrin-recognition domain on ICln (AKFEEE, 10–100 μm) also inhibits platelet function. Thus, we have identified, verified, and characterized a novel functional interaction between the platelet integrin and ICln, in the platelet membrane.